Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Common Equity (2016 - 2025)

Sangamo Therapeutics (SGMO) has 16 years of Common Equity data on record, last reported at $6.2 million in Q3 2025.

  • For Q3 2025, Common Equity fell 84.05% year-over-year to $6.2 million; the TTM value through Sep 2025 reached $6.2 million, down 84.05%, while the annual FY2024 figure was $22.8 million, 72.53% down from the prior year.
  • Common Equity reached $6.2 million in Q3 2025 per SGMO's latest filing, down from $19.6 million in the prior quarter.
  • Across five years, Common Equity topped out at $469.4 million in Q1 2021 and bottomed at $4.9 million in Q1 2025.
  • Average Common Equity over 5 years is $206.0 million, with a median of $233.6 million recorded in 2023.
  • Peak YoY movement for Common Equity: rose 19.02% in 2021, then crashed 91.35% in 2025.
  • A 5-year view of Common Equity shows it stood at $375.3 million in 2021, then fell by 21.42% to $295.0 million in 2022, then plummeted by 71.9% to $82.9 million in 2023, then crashed by 72.53% to $22.8 million in 2024, then plummeted by 72.58% to $6.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $6.2 million in Q3 2025, $19.6 million in Q2 2025, and $4.9 million in Q1 2025.